Statement: 60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule.
Primary_evidence: Outcome Measurement:    Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule   Feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with > 85% of the protocol-specified dose.   Time frame: From the start of treatment through the neoadjuvant treatment period (approximately 20 weeks) Results 1:    Arm/Group Title: Neoadjuvant Therapy   Arm/Group Description: Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments.   Overall Number of Participants Analyzed: 30   Measure Type: Number   Unit of Measure: percentage of participants  60